Price History

Hover for the daily close. The dotted line marks the period open.

Compare GERN with… →

GERN Key Statistics

As of Sep 4, 2026

Trading

Open: $1.49
Previous Close: $1.51
Day's Range: 1.46–1.59
52-Week Range: 1.04–2.01
Volume: 11.48M
Beta: 0.60

Valuation

Market Cap: $1.01B
P/E Ratio: unprofitable
Forward P/E: 39.25
P/S ratio: 4.93
EPS (ttm): −0.11

Financials (FY)

Revenue (FY): $183.88M+138.83%
Net Income (FY): −$83.50M
Profit margin: −33.05%
Shares Outstanding: 642.47M
1-Year Return: +13.77%

Dividend and dates

Earnings Date: November 4, 2026
Avg Volume: 11.82M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GERN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+98.36%−62.71%+18.94%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	+18.94%
2025	−62.71%
2024	+67.77%
2023	−12.81%
2022	+98.36%
2021	−23.27%
2020	+16.91%
2019	+36.00%
2018	−44.44%
2017	−13.04%
2016 (partial year)	−23.90%

As of September 4, 2026.

GERN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$183.88M	−$83.50M	−45.4%
2024	$76.99M	−$174.57M	−226.7%
2023	$237.00K	−$184.13M	−77690.7%
2022	$596.00K	−$141.90M	−23808.9%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$183.88M	$179.14M	−$51.55M	−$83.50M	−45.4%
2024	$76.99M	$75.74M	−$173.73M	−$174.57M	−226.7%
2023	$237.00K	$237.00K	−$193.94M	−$184.13M	−77690.7%
2022	$596.00K	$596.00K	−$138.55M	−$141.90M	−23808.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GERN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	GERN	Biotechnology median	vs median
P/S ratio	4.93	15.26	0.3x the median
Profit margin	−33.05%	0.00%	33.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Geron Corporation (GERN) is capitalised at $1.01B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 258.

The 52-week range on file runs from $1.04 to $2.01. The most recent close on file for GERN is $1.57, dated September 4, 2026. That is +$0.06 (+3.97%) against the previous close. The latest close sits 50.96% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $183.88M. That is +138.83% against the prior fiscal year, when revenue was $76.99M. The same year closed with a net loss of $83.50M. Profit margin runs at −33.05%. That is 33.1 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.11.

Across the 4 fiscal years on file, revenue moves from $596.00K in 2022 to $183.88M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 39.25. The price-to-sales ratio is 4.93. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.61. Annualized volatility over the trailing 10 years is 78.51%. The trailing one-year price return is +13.77%. Across 10 years the annualized return works out at −5.45%.

Growth & Income

The record shows no dividend for GERN.

So far in 2026 the price is +18.94%. The strongest complete calendar year on file is 2022 at +98.36%; the weakest is 2025 at −62.71%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Geron Corporation (GERN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Geron Corporation	GERN	$1.01B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Geron Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Geron Corporation

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Visit website →

Geron Corporation (GERN) Stock Analysis